Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 12/20 | 0.58 |
| ▸ | LPL | P06858 | 11/20 | 0.58 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MMP3 | P08254 | 1/20 | 0.40 |
| ▸ | TDP2 | O95551 | 1/20 | 0.38 |
| ▸ | F11 | P03951 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL521491 | 0.85 | LIPG (0.63) | LIPGLPLESR2TDP2F11 | |
| SCHEMBL1163929 | 0.80 | ESR2 (0.59) | LIPGLPLESR2F11 | |
| SCHEMBL18332737 | 0.80 | LIPG (0.69) | LIPGLPLESR2F11 | |
| SCHEMBL1284463 | 0.79 | LIPG (0.63) | LIPGLPLESR2ENPP2F11 | |
| SCHEMBL1331631 | 0.79 | LIPG (0.63) | LIPGLPLENPP2F11 | |
| SCHEMBL3039403 | 0.79 | LIPG (0.63) | LIPGLPLESR2F11 | |
| SCHEMBL23071684 | 0.78 | LIPG (0.70) | LIPGLPLF11 | |
| SCHEMBL12215735 | 0.78 | LIPG (0.80) | LIPGLPLESR2F11 | |
| Hydrochloric Acid SCHEMBL1631610 | 0.78 | LIPG (0.61) | LIPGLPLENPP2F11 | |
| SCHEMBL30477495 | 0.78 | LIPG (0.80) | LIPGLPLESR2F11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388599-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-20240199525-A1 | SHP2-Targeting Small Molecules For Use As Anti-Cancer Agents | WEST VIRGINIA UNIV BOARD OF GOVERNORS ON BEHALF OF WEST VIRGINIA UNIV (US) | 2024-06-20 | — | — | US | disclosed |
| US-12012409-B2 | Bicyclic heterocycles as FGFR inhibitors | INCYTE CORPORATION (US) | 2024-06-18 | — | — | US | disclosed |
| CN-116969987-A | Method for preparing 1,2,3, 4-disilyl tetrahydroquinoline compound by utilizing chitosan Schiff base copper functional material | 众力百捷(湖北)科技有限公司 | 2023-10-31 | — | — | CN | disclosed |
| US-20220348593-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2022-11-03 | — | — | US | disclosed |
| US-20220332718-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | GENENTECH, INC. (US) | 2022-10-20 | — | — | US | disclosed |
| US-11390610-B2 | Piperazine derivatives as MAGL inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2022-07-19 | — | — | US | disclosed |
| US-20220169642-A1 | COMPOUNDS FOR THE TREATMENT OF ONCOVIRUS INDUCED CANCER AND METHODS OF USE THEREOF | CELLESTIA BIOTECH AG (CH) | 2022-06-02 | — | — | US | disclosed |
| EP-3953335-A1 | INHIBITORS OF NOTCH SIGNALLING PATHWAY AND USE THEREOF IN TREATMENT OF CANCERS | Cellestia Biotech AG (CH) | 2022-02-16 | — | — | EP | disclosed |
| US-11136326-B2 | Pyrrolopyrimidine derivatives as TAM inhibitors | INCYTE CORPORATION (US) | 2021-10-05 | — | — | US | disclosed |
| US-8008481-B2 | Indazole compounds | ABBVIE INC. | 2011-08-30 | — | — | US | disclosed |
| US-20100204221-A1 | Pyrrolopyrimidinyl axl kinase inhibitors | TOLERO PHARMACEUTICALS, INC. | 2010-08-12 | — | — | US | disclosed |
| US-20100204221-A1 | Pyrrolopyrimidinyl axl kinase inhibitors | TOLERO PHARMACEUTICALS, INC. | 2010-08-12 | — | — | US | disclosed |
| US-20100204221-A1 | Pyrrolopyrimidinyl axl kinase inhibitors | TOLERO PHARMACEUTICALS, INC. | 2010-08-12 | — | — | US | disclosed |
| WO-2010090764-A1 | PYRROLOPYRIMIDINYL AXL KINASE INHIBITORS | SUPERGEN, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
| WO-2010090764-A1 | PYRROLOPYRIMIDINYL AXL KINASE INHIBITORS | SUPERGEN, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
| US-20090048258-A1 | Amide Compound | TAKEDA, PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-02-19 | — | — | US | disclosed |
| US-20070282101-A1 | Indazole compounds | ABBVIE INC. | 2007-12-06 | — | — | US | disclosed |
| EP-1845081-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-10-17 | — | — | EP | disclosed |
| US-6294573-B1 | FOR THERAPY RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, OSTEOPENIAS SUCH AS OSTEOPOROSIS, PERIODONTITIS, GINGIVITIS, CORNEAL, EPIDERMAL OR GASTRIC ULCERATION, AND TUMOR GROWTH AND METASTASIS OR INVASION | ABBOTT LABORATORIES | 2001-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12012409-B2 | Bicyclic heterocycles as FGFR inhibitors | FGFR3, FGFR2, FGFR1 | LIPG 1939/4885LPL 2418/4885ESR2 1074/4885 |
| US-20100204221-A1 | Pyrrolopyrimidinyl axl kinase inhibitors | AXL, FLT3, TYRO3 | LIPG 2466/4885LPL 3796/4885ESR2 2850/4885 |
| US-20220169642-A1 | COMPOUNDS FOR THE TREATMENT OF ONCOVIRUS INDUCED CANCER AND METHODS OF USE THEREOF | NOTCH1, NOTCH4, NOTCH2 | LIPG 1717/4885LPL 4341/4885ESR2 1442/4885 |
| US-20070282101-A1 | Indazole compounds | CYP3A43, CYP3A7, UGT1A1 | LIPG 3363/4885LPL 3658/4885ESR2 2050/4885 |
| US-11136326-B2 | Pyrrolopyrimidine derivatives as TAM inhibitors | FLT3, MERTK, MIF | LIPG 1588/4885LPL 3867/4885ESR2 1114/4885 |
| US-11390610-B2 | Piperazine derivatives as MAGL inhibitors | MAGI3, PYM1, MAG | LIPG 2367/4885LPL 1351/4885ESR2 4722/4885 |
| US-20220348593-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, MTOR | LIPG 1634/4885LPL 3869/4885ESR2 1480/4885 |
| US-20240199525-A1 | SHP2-Targeting Small Molecules For Use As Anti-Cancer Agents | PTPRO, PTPRC, PTPRCAP | LIPG 2101/4885LPL 3731/4885ESR2 1428/4885 |
| US-20220332718-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | IRAK1, IRAK4, IRAK2 | LIPG 4695/4885LPL 4543/4885ESR2 2798/4885 |
| US-20090048258-A1 | Amide Compound | DLAT, DGAT1, DGAT2 | LIPG 2847/4885LPL 1611/4885ESR2 584/4885 |
| US-20250388599-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3C2B, PIK3C2A, PIK3R1 | LIPG 1906/4885LPL 3263/4885ESR2 425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.